Shares of Accuray Inc. (NASDAQ:ARAY) rose 4.9% on Wednesday . The company traded as high as $5.77 and last traded at $5.75, with a volume of 1,073,167 shares traded. The stock had previously closed at $5.48.

ARAY has been the topic of a number of recent research reports. Morgan Stanley reaffirmed a “hold” rating on shares of Accuray in a research report on Wednesday, April 27th. Brean Capital reissued a “buy” rating and issued a $12.00 target price on shares of Accuray in a report on Sunday, May 22nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $8.58.

The company’s 50-day moving average is $5.36 and its 200-day moving average is $5.41. The firm’s market cap is $465.31 million.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Wednesday, August 17th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.02. The company had revenue of $95 million for the quarter, compared to analyst estimates of $98.97 million. Accuray’s revenue was down 6.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.07) earnings per share. On average, equities research analysts expect that Accuray Inc. will post ($0.27) EPS for the current fiscal year.

A hedge fund recently raised its stake in Accuray stock. Wells Fargo & Company MN increased its stake in Accuray Inc. (NASDAQ:ARAY) by 20.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,656,069 shares of the company’s stock after buying an additional 286,458 shares during the period. Wells Fargo & Company MN owned 2.05% of Accuray worth $11,178,000 as of its most recent filing with the SEC.

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.